Fairfield Financial Advisors’s AstraZeneca AZN Stock Holding History

Fairfield Financial Advisors’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-1,121	Closed	-$147K	–	81
2024 Q4	$147K	Sell	1,121 -295	-21%	-$41.3K	0.05%	76
2024 Q3	$221K	Sell	1,416 -73	-5%	-$11.8K	0.08%	67
2024 Q2	$232K	Buy	+1,489	New	+$224K	0.07%	61
2023 Q4	$168K	Buy	1,245 +467	+60%	+$60.7K	0.06%	81
2023 Q3	$105K	Sell	778 -144	-16%	-$19.7K	0.04%	94
2023 Q2	$132K	Hold	922	–	–	0.05%	81
2023 Q1	$128K	Buy	922 +13	+1%	+$1.75K	0.06%	86
2022 Q4	$123K	Hold	909	–	–	0.06%	87
2022 Q3	$99.7K	Sell	909 -68	-7%	-$8.63K	0.05%	88
2022 Q2	$129K	Hold	977	–	–	0.06%	77
2022 Q1	$130K	Buy	+977	New	+$117K	0.05%	76

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Sanders Capital West Palm Beach, Florida $99.8B AUM 47.9% 1-Year Est. Return

Fairfield Financial Advisors's AZN Position: Q1 2025 in Review

Fairfield Financial Advisors sold out of AstraZeneca (AZN) in Q1 2025, closing a stake of 1,121 shares — an estimated $147K sold.

Fairfield Financial Advisors first reported a position in AZN in Q1 2022 and held it in 11 quarters. The position peaked at $232K in Q2 2024. 1,252 funds tracked by Wall St. Rank hold AZN as of Q1 2025.

Fairfield Financial Advisors reported no remaining AstraZeneca position as of Q1 2025 after selling out during the quarter.
Fairfield Financial Advisors sold 1,121 AstraZeneca shares in Q1 2025, an estimated $147K.
Fairfield Financial Advisors first reported a position in AstraZeneca in Q1 2022 and held it in 11 quarters.
Fairfield Financial Advisors's AstraZeneca position peaked at $232K in Q2 2024.
1,252 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2025.

Based on Fairfield Financial Advisors's 13F filing for Q1 2025, filed 9 May 2025.